NO20053185L - Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse. - Google Patents

Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.

Info

Publication number
NO20053185L
NO20053185L NO20053185A NO20053185A NO20053185L NO 20053185 L NO20053185 L NO 20053185L NO 20053185 A NO20053185 A NO 20053185A NO 20053185 A NO20053185 A NO 20053185A NO 20053185 L NO20053185 L NO 20053185L
Authority
NO
Norway
Prior art keywords
treatment
hyperactivity disorder
attention
failure
attention failure
Prior art date
Application number
NO20053185A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053185D0 (no
Inventor
Jr Vincent Edward Groppi
Donn Gregory Wishka
Eric Jon Jacobsen
Jason Kenneth Myers
David Walter Piotrowski
Bruce Nelsen Rogers
Daniel Patrick Walker
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20053185D0 publication Critical patent/NO20053185D0/no
Publication of NO20053185L publication Critical patent/NO20053185L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20053185A 2002-12-11 2005-06-29 Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse. NO20053185L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43258602P 2002-12-11 2002-12-11
PCT/IB2003/005542 WO2004052461A1 (en) 2002-12-11 2003-11-28 Combination for the treatment of adhd

Publications (2)

Publication Number Publication Date
NO20053185D0 NO20053185D0 (no) 2005-06-29
NO20053185L true NO20053185L (no) 2005-08-17

Family

ID=32507968

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053185A NO20053185L (no) 2002-12-11 2005-06-29 Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.

Country Status (23)

Country Link
US (1) US20050107425A1 (is)
EP (1) EP1572300A1 (is)
JP (1) JP2006510663A (is)
KR (1) KR20050085538A (is)
CN (1) CN1735441A (is)
AP (1) AP2005003336A0 (is)
AU (1) AU2003283656A1 (is)
BR (1) BR0317229A (is)
CA (1) CA2509142A1 (is)
CO (1) CO5700801A2 (is)
CR (1) CR7868A (is)
EA (1) EA200500783A1 (is)
EC (1) ECSP055852A (is)
HR (1) HRP20050522A2 (is)
IS (1) IS7858A (is)
MA (1) MA27606A1 (is)
MX (1) MXPA05006336A (is)
NO (1) NO20053185L (is)
OA (1) OA12969A (is)
PL (1) PL377552A1 (is)
TN (1) TNSN05158A1 (is)
WO (1) WO2004052461A1 (is)
ZA (1) ZA200504338B (is)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
WO2005092890A2 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
CA2681934A1 (en) * 2007-03-28 2008-10-02 High Point Pharmaceuticals, Llc 11beta-hsd1 active compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
MX2010009110A (es) * 2008-02-19 2010-11-30 Adolor Corp Beloxepina, sus enantiomeros, y analogos de la misma para el tratamiento de dolor.
BRPI0921299A2 (pt) 2008-11-21 2015-08-25 High Point Pharmaceuticals Llc Compostos de benzamida adamantila
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
US12691083B2 (en) 2021-08-19 2026-07-28 Dankook University Cheonan Campus Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder, containing KDS2010 as active ingredient
WO2023022269A1 (ko) 2021-08-20 2023-02-23 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
KR102597711B1 (ko) 2021-08-20 2023-11-06 단국대학교 천안캠퍼스 산학협력단 Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
KR102684933B1 (ko) 2021-08-20 2024-07-16 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
CO5700801A2 (es) 2006-11-30
CR7868A (es) 2005-07-08
IS7858A (is) 2005-05-23
JP2006510663A (ja) 2006-03-30
EA200500783A1 (ru) 2005-12-29
PL377552A1 (pl) 2006-02-06
CN1735441A (zh) 2006-02-15
KR20050085538A (ko) 2005-08-29
HRP20050522A2 (en) 2005-12-31
TNSN05158A1 (fr) 2007-05-14
EP1572300A1 (en) 2005-09-14
ECSP055852A (es) 2005-09-20
AU2003283656A1 (en) 2004-06-30
MA27606A1 (fr) 2005-11-01
ZA200504338B (en) 2006-07-26
MXPA05006336A (es) 2005-08-26
WO2004052461A1 (en) 2004-06-24
US20050107425A1 (en) 2005-05-19
BR0317229A (pt) 2005-11-01
NO20053185D0 (no) 2005-06-29
OA12969A (en) 2006-10-13
CA2509142A1 (en) 2004-06-24
AP2005003336A0 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
EA200500783A1 (ru) Комбинация для лечения синдрома дефицита внимания с гиперактивностью
PL372372A1 (en) Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
NO20100077L (no) Behandling med alfa7-selektive ligander
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
NO20054343L (no) Behandling av immunologiske lidelser ved anvendelse av agonister av interleukin-21/interleukin-21 reseptor
NO20062003L (no) Fremgangsmate og forbindelser for behandling av immunoinflammatoriske forstyrrelser
EA199800620A1 (ru) Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
ATE405670T1 (de) Autoimmunerkrankungen und nadph-oxidase-defekte
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
EA199800152A1 (ru) Лечение синдрома дефицита внимания/гиперактивности
WO2004052858A3 (en) Inhibitors of monoamine uptake
DE60229123D1 (de) Behandlung von fibromyalgie mit pindolol
BRPI0515376A (pt) método para prevenir ou tratar diarréia em um mamìfero, composição útil na prevenção ou no tratamento de diarréia em um mamìfero, kit adequado para administrar um exopolissacarìdeo microbiano a um mamìfero, e, meio para comunicar informação
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
FI20031191A7 (fi) Monoamiinin takaisinoton estäjä
NO20081200L (no) Polyalkyleniminer og polyalkylenakrylamidsalt for syregass scrubbingprosess
DE69923559D1 (de) Methoden zur inhibierung von helicobacter pylori
DK1513529T3 (da) Tredobbelte monoamin-genoptagelsesinhibitorer til behandling af kronisk smerte
EA200801296A1 (ru) Способ лечения метаболического синдрома